A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms of the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infecti...
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV))-associated lower respiratory tract infec...
Scully, M;
Rayment, R;
Clark, A;
Westwood, J. P;
Cranfield, T;
Gooding, R;
Bagot, C. N;
Taylor, A;
Sankar, V;
Gale, D;
Dutt, T;
McIntyre, J;
Lester, W.
The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement-mediated haemolytic uraemic syndrome (CM HUS); these ar...
Chalmers, James;
Crichton, Megan;
Goeminne, Pieter;
Cao, Bin;
Humbert, Marc;
Shteinberg, Michal;
Antoniou, Katerina;
Suppli Ulrik, Charlotte;
Parks, Helen;
Wang, Chen;
Vandendriessche, Thomas;
Qu, Jieming;
Stolz, Daiana;
Brightling, Christopher;
Welte, Tobias;
Aliberti, Stefano;
Simonds, Anita;
Tonia, Thomy;
Roche, Nicolas.
Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of SARS-CoV-2 infection have a high mortality rate and frequently require noninvasive respiratory support or invasive ventilation. Optimising and standardising management through evidence-based guidelines may improve quality of ca...
Zinzani, Pier Luigi;
Marchetti, Monia;
Billio, Atto;
Barosi, Giovanni;
Carella, Angelo Michele;
Lazzarino, Mario;
Martelli, Maurizio;
Rambaldi, Alessandro;
Rigacci, Luigi;
Tarella, Corrado;
Vitolo, Umberto;
Tura, Sante.
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
Anticuerpos Monoclonales,
Anticuerpos,
Anticuerpos Monoclonales de Origen Murino/uso terapéutico,
Antineoplásicos,
Esquema de Medicación,
Trasplante de Células Madre Hematopoyéticas,
Linfoma Folicular/patología,
Linfoma/terapia,
Estadificación de Neoplasias,
Rituximab,
Factores de Tiempo
